Search

Your search keyword '"Klar, Richard"' showing total 112 results

Search Constraints

Start Over You searched for: Author "Klar, Richard" Remove constraint Author: "Klar, Richard"
112 results on '"Klar, Richard"'

Search Results

1. Human angiotensin-converting enzyme 2–specific antisense oligonucleotides reduce infection with SARS-CoV-2 variants

7. 881 Knockdown of neuropilin-1 by third generation antisense oligonucleotides has strong antitumor activity that can be further increased by combination with immune checkpoint inhibitors

8. Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice

9. Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity

10. Supplementary Information from Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis

11. Supplementary Material and Methods from Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis

12. Data from Immuno-PET Imaging of Engineered Human T Cells in Tumors

13. Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity

14. Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression

15. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression

17. 434 Targeting the expression of Neuropilin-1 by locked nucleic acid modified antisense oligonucleotides results in potent anti-tumor activity in vivo

18. Abstract 4149: Knock-down of Neuropilin-1 by locked nucleic acid antisense oligonucleotides facilitates cancer immune control

20. CHOP-ASO Ameliorates Glomerular and Tubular Damage on Top of ACE Inhibition in Diabetic Kidney Disease

23. Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis

29. Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer

30. Additional file 4: of Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity

35. Abstract 5021: LNAplusTMantisense oligonucleotides targeting CD39 and CD73 have potent anti-tumor activity by modulating immunosuppressive tumor microenvironment

37. Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer

39. Identification of naturally presented HLA ligands on the surface of healthy and malignant hematopoetic cells and their therapeutic potential as targets for TCR-transgenic T cells

41. Identification of naturally presented HLA ligands on the surface of healthy and malignant hematopoetic cells and their therapeutic potential as targets for TCR-transgenic T cells

42. Identification of naturally presented HLA ligands on the surface of healthy and malignant hematopoetic cells and their therapeutic potential as targets for TCR-transgenic T cells

43. In-depth Characterization of a TCR-specific Tracer for Sensitive Detection of Tumor-directed Transgenic T Cells by Immuno-PET

44. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry

45. Abstract 3202: Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity

46. Immuno-PET Imaging of Engineered Human T Cells in Tumors

47. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T Cells specifically inhibit Ewing sarcoma growth in vitro and in vivo

48. Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity

49. ITOC2 – 021. The melanoma immune-peptidome for T-cell-based anti-tumour immunotherapies

Catalog

Books, media, physical & digital resources